Thursday, June 25, 2026

QA/QC Tools - GMP - FDA - EMA

Audit Readiness Checklist

Self-assess GMP inspection readiness across documentation, pharmaceutical quality system, CAPA, deviations, validation, data integrity, facilities, and equipment. Built for QA leads, quality managers, and inspection response teams — then verify against site SOPs and regulatory guidance.

Quick Answer

GMP audit readiness is the documented state of being prepared for FDA, EMA, or PIC/S inspection. Quality teams score documentation, pharmaceutical quality system governance, CAPA effectiveness, validation status, data integrity controls, and facility readiness against objective evidence. This interactive checklist produces a risk-based readiness score and prioritized gap action list for self-inspection and pre-approval inspection preparation — reconcile results with site SOPs and current ICH Q10/Q9 guidance.

Inspection readiness score

Mark checklist items below to generate a readiness view and prioritized gap list.

0%

Mark checklist items to generate a readiness view.

0reviewed
0gaps
0N/A

FDA/EMA GMP Readiness Checklist

Use documentary evidence when scoring. Examples include approved SOPs, training records, audit reports, batch records, deviation files, validation protocols, data audit trails, calibration logs, and environmental monitoring records.

Documentation and Record Control

Current approved SOPs are available for GMP-critical operations and reflect actual practice.

Batch production and laboratory records are complete, attributable, legible, contemporaneous, original, and accurate.

Document change history, periodic review, retention, and archival processes are controlled.

Pharmaceutical Quality System

Management review evaluates quality metrics, recurring deviations, complaints, recalls, and CAPA effectiveness.

Quality risk management is documented and aligned with ICH Q9 principles.

Supplier qualification and quality agreements are current for critical materials and services.

CAPA, Deviations, OOS and Complaints

Deviation and OOS investigations identify root cause, product impact, and scientifically justified conclusions.

CAPA actions have owners, due dates, verification of effectiveness, and overdue escalation.

Complaint, recall, and field alert processes are tested and traceable to batch distribution records.

Process, Cleaning and Computerized System Validation

Process validation lifecycle files include approved protocols, reports, CPP/CQA rationale, and continued process verification.

Cleaning validation limits, sampling plans, recovery factors, and residue methods are justified and current.

Computerized systems have validation status, access control, backup/restore testing, and change control evidence.

Data Integrity and Laboratory Controls

Audit trails for critical GMP systems are enabled, reviewed, and linked to defined procedures.

Analytical methods, reference standards, sample handling, and chromatographic integration practices are controlled.

User access, shared accounts, electronic signatures, and privileged permissions are periodically reviewed.

Facilities, Utilities and Equipment

Critical utilities, HVAC, water systems, and cleanrooms are qualified, monitored, and maintained within alert/action limits.

Calibration and preventive maintenance records are current for GMP-critical instruments and equipment.

Line clearance, material/personnel flow, pest control, and housekeeping controls are inspection-ready.

Gap Action List

Items marked partial or fail will appear here with suggested remediation priority.

    How to Interpret the Score

    85-100% Inspection-ready signal Confirm evidence quality and staff interview readiness.
    65-84% Targeted remediation needed Prioritize high-risk gaps and overdue CAPA.
    Below 65% Significant readiness risk Escalate to quality leadership before inspection-facing activity.

    Pharma & inspection context

    GMP audit readiness is a core responsibility under ICH Q10 pharmaceutical quality system and EU GMP Chapter 9 self-inspection requirements. Sponsors, CMOs, and API manufacturers use structured readiness assessments before FDA pre-approval inspections, EMA GMP inspections, client audits, and remediation milestones following prior 483 observations or warning letters.

    This checklist integrates with the NovaPharmaNews QA/QC hub: generate site-specific checklists with the GMP Checklist Generator, prioritize process failures with the RPN Calculator, assess process capability with Process Capability Cpk, and calculate cleaning validation limits with the Cleaning Validation Limit tool.

    Inspection readiness should link to management review metrics, deviation trending, CAPA overdue reports, and validation status dashboards. Document self-inspection findings in the quality system and track closure before scheduling regulatory-facing activities.

    Evidence & sources

    Frequently Asked Questions

    GMP audit readiness is the documented state of being prepared for FDA, EMA, WHO, or PIC/S regulatory inspection. It includes current approved procedures, complete and attributable batch records, effective CAPA with verified effectiveness, validated processes and cleaning methods, computerized system controls, data integrity safeguards, trained personnel who can explain their work, and facility and utility qualification evidence. Readiness is demonstrated through objective records — not checklist completion alone.
    Scoring should be risk based and defined in the site quality system per ICH Q9 quality risk management. This educational checklist uses pass, partial, fail, and not applicable statuses to identify high-priority gaps. Partial scores half credit; fail scores zero. Not applicable items are excluded from the percentage. Reconcile the output with internal SOPs, approved quality plans, and management review expectations before inspection-facing activity.
    Common inspection focus areas include pharmaceutical quality system governance and management review, batch production and laboratory records, deviations and OOS/OOT investigations, CAPA effectiveness, process and cleaning validation lifecycle files, computerized systems and data integrity (Annex 11 / 21 CFR Part 11), facilities and utilities qualification, equipment calibration and maintenance, personnel training and qualification, and supplier and contract manufacturing oversight.
    No. A checklist score is only a readiness signal. Inspectors evaluate actual evidence on the floor, record consistency across batches, staff interview responses, product risk profile, historical 483 or warning letter findings, and how effectively the quality system detects and corrects problems. A high score with shallow evidence or untrained staff will not satisfy a competent inspector.
    Many pharmaceutical sites perform annual GMP self-inspections per EU GMP Chapter 9 and more frequent targeted readiness checks before expected inspections, pre-approval inspections (PAI), major submissions, technology transfers, significant process changes, or remediation milestones following prior regulatory findings.
    Self-inspection (internal audit) is conducted by the site quality unit to proactively identify gaps before regulators arrive. Regulatory GMP inspections are conducted by FDA, EMA, or national authorities with legal authority to issue 483 observations, warning letters, or import alerts. Self-inspection findings should feed CAPA and management review; regulatory findings require formal response within mandated timelines.
    A PAI is an FDA inspection of manufacturing facilities before approving a new drug application (NDA) or biologics license application (BLA). PAI readiness emphasizes process validation status, analytical method validation, stability data integrity, facility fit for the proposed process, and whether the site can reliably manufacture at commercial scale. PAI checklists should emphasize validation packages, tech transfer records, and batch records from exhibit batches — not just routine GMP housekeeping.
    ALCOA+ stands for Attributable, Legible, Contemporaneous, Original, Accurate — plus Complete, Consistent, Enduring, and Available. FDA and EMA data integrity guidance expect GMP records to meet these principles. Inspectors frequently cite incomplete batch records, backdated entries, shared logins, missing audit trails, and undocumented changes. Audit readiness checklists should verify ALCOA+ compliance in both paper and electronic systems.
    CAPA effectiveness verification confirms that corrective and preventive actions actually resolved the root cause — not just closed the record. Evidence includes post-CAPA batch data, repeat deviation rates, re-validation results, updated training records, and follow-up audits. Inspectors often request CAPA files from prior 483 observations; overdue or ineffective CAPA is a common repeat finding.
    Annex 1 (sterile manufacture), Annex 11 (computerized systems), Annex 15 (qualification and validation), and Annex 16 (QP certification) are frequently cited during EU inspections. Finished dosage sites also rely on Chapters 1 (PQS), 4 (documentation), and 8 (complaints and recalls). Align checklist items with the dosage form and technology at your site.
    Personnel should be able to explain their role, locate relevant SOPs, describe deviation handling steps, and demonstrate data entry practices without coaching. Mock interviews during self-inspection identify knowledge gaps before regulators arrive. Avoid scripting responses — inspectors detect rehearsed answers. Training records should demonstrate role-specific GMP qualification.
    No. This checklist is an educational readiness aid for gap identification and prioritization. It does not replace qualified internal auditors, third-party GMP audits, regulatory intelligence monitoring, or site-specific inspection history review. Confirm every finding against current FDA, EMA, ICH, WHO, and local GMP requirements plus approved SOPs before inspection decisions.

    Related Tools